Rocket Pharmaceuticals

167 articles with Rocket Pharmaceuticals

• Rocket Pharmaceuticals to Participate in the 43rd Annual Cowen Health Care Conference

  3/1/2023

  Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) today announced that Gaurav Shah, M.D., Chief Executive Officer, is scheduled to participate in the Genetic Medicines Corporate Panel at the 43rd Annual Cowen Health Care Conference taking place in Boston, MA on Monday, March 6, 2023 at 10:30 a.m. ET.

• Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial and Operational Results

  2/27/2023

  Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and operational results for the fourth quarter and year ended December 31, 2022.

• Rocket Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference

  2/9/2023

  Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) today announced that Gaurav Shah, M.D., Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the SVB Securities Global Biopharma Conference on Thursday, February 16, at 2:20 p.m. ET.

• Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A501 Gene Therapy for Danon Disease

  2/7/2023

  Rocket Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to RP-A501.

• Rocket Pharmaceuticals Expands Cardiac Gene Therapy Portfolio with Addition of RP-A601 for PKP2-ACM and Announces Positive Updated Phase 1 Data for RP-A501 in Danon Disease

  1/9/2023

  Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) today announces the addition of RP-A601 to Rocket’s cardiac gene therapy portfolio as well as anticipated highlights for the year ahead across the Company’s world-class pipeline of lentiviral and AAV gene therapy programs targeting rare hematologic and cardiovascular diseases.

• 

  Executives Reunite at JPM as Biotech Kicks Off 2023

  1/5/2023

  JP Morgan week is shaping up to approximate pre-pandemic attendance levels as executives return to San Francisco after two years of COVID-19-enforced absences.

• Rocket Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference

  1/3/2023

  Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) today announces that Gaurav Shah, M.D., Chief Executive Officer, is scheduled to present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023, at 2:15 p.m. PT.

• Rocket Pharmaceuticals Provides Update on Anticipated Registration Path for RP-A501 in Danon Disease Following End-of-Phase 1 FDA Meeting

  12/22/2022

  Rocket Pharmaceuticals, Inc. today announces updates from the Company's end-of-Phase 1 meeting with the U.S. Food and Drug Administration (FDA) regarding RP-A501, the Company's investigational adeno-associated virus (AAV)-based gene therapy for Danon Disease.

• Rocket Pharmaceuticals Presents Positive Clinical Data from Fanconi Anemia, Pyruvate Kinase Deficiency and Severe Leukocyte Adhesion Deficiency-I Programs at the 64th American Society of Hematology (ASH) Annual Meeting

  12/12/2022

  Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today announces positive clinical data from its lentiviral (LV)-based gene therapy programs at the 64th American Society of Hematology (ASH) Annual Meeting.

• Rocket Pharmaceuticals Completes Acquisition of Renovacor

  12/1/2022

  Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) today announces that it has completed the previously announced acquisition of Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases.

• Rocket Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference

  11/21/2022

  Rocket Pharmaceuticals, Inc. today announces that Gaurav Shah, M.D., Chief Executive Officer, will participate in a fireside chat at the 5th Annual Evercore ISI HealthCONx Conference.

• Rocket Pharmaceuticals Announces Presentations Highlighting AAV and Lentiviral Gene Therapies at Upcoming Scientific Congresses

  11/3/2022

  Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage, clinical biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today announces upcoming data presentations at the 75th American Heart Association (AHA) Annual Meeting, taking place in Chicago, Illinois, and virtually, from Nov. 5-7, 2022, and the 64th American Society of Hematology (ASH) Annual Meeting.

• Rocket Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Progress

  11/3/2022

  Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage, clinical biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today reports financial results for the quarter ending September 30, 2022, and updates from the Company’s key pipeline developments, business operations and upcoming milestones.

• Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral Gene Therapies at the 29th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)

  10/12/2022

  Rocket Pharmaceuticals, Inc. announces data presentations at the 29th Annual Congress of the European Society of Gene & Cell Therapy in Edinburgh, United Kingdom, taking place October 11-14, 2022.

• Rocket Pharmaceuticals to Present at the 2022 Cell & Gene Meeting on the Mesa

  10/10/2022

  Rocket Pharmaceuticals, Inc. today announced that Raj Prabhakar, M.B.A., Chief Business Officer, will deliver an in-person company presentation at the 2022 Cell & Gene Meeting on the Mesa on Tuesday, October 11, at 2:30 p.m. PT in Carlsbad, CA.

•  Rocket Pharmaceuticals Announces Pricing of Public Offering of Common Stock - October 04, 2022

  10/4/2022

  Rocket Pharmaceuticals, Inc. announced the pricing of an underwritten public offering of 6,800,000 shares of its common stock at a public offering price of $14.75 per share.

• Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock - October 03, 2022

  10/3/2022

  Rocket Pharmaceuticals, Inc., a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of investigational genetic therapies for rare childhood disorders with high unmet need, announced that it has commenced an underwritten public offering of $100 million of shares of its common stock.

•  Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial for RP-A501 in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022

  9/30/2022

  Rocket Pharmaceuticals, Inc. announces positive clinical updates from its Phase 1 Danon Disease Trial for RP-A501 through an oral poster session at the Heart Failure Society of America Annual Scientific Meeting 2022.

• 

  Rocket Takes Off on Early Data from Danon Gene Therapy

  9/30/2022

  Shares of Rocket Pharmaceuticals jumped Friday morning after the company announced positive clinical updates from a Phase I study of patients diagnosed with Danon disease.

• Rocket Pharmaceuticals to Present at Chardan 6th Annual Genetic Medicines Conference

  9/27/2022

  Rocket Pharmaceuticals to Present at Chardan 6th Annual Genetic Medicines Conference.